CJC-1295 Ipamorelin

Editorial policy · in force since 21 Sep 2026

Editorial policy for cjc-1295-ipamorelin.com

Nine rules, applied to every page. They are short because they are meant to be checked, not admired.

Published 21 Sep 2026Updated 23 Sep 20264 min read
sources, each read in full
34
DOI or trial number checked
28
testimonials, pixels or ads
0

Figure 1

The 34 sources cited on this site

Every DOI and trial number resolved on its registry before publication; a reference that does not answer is not cited. Each guide lists its own sources at the end of the page.

The nine rules at a glance

1. Sources

A claim about what a peptide does in a living organism is supported by a peer-reviewed publication or a registered clinical trial, cited on the same page. Every DOI is verified on the CrossRef API and every NCT number on the ClinicalTrials.gov API before publication; a reference that does not resolve is not used. Regulatory statements cite the agency page they come from. Secondary sources (clinic pages, forums, supplier pages, encyclopaedias) are never cited as evidence.

2. Numbers

A number is quoted as the source states it, in the source's units, with the population and the duration it applies to. Fold-changes, percentages and half-lives are never rounded into stronger claims. Search volumes quoted on the site are monthly figures from Google Ads data, measured in September 2026; where Google Ads returns no figure for a term, the site says so.

3. Doses

The site gives no doses, schedules or protocols for any compound. It reports what the published studies measured, with the population and DOI. CJC-1295 and ipamorelin are research compounds, not approved medicines, sold for research use only.

4. Effects

The site does not describe effects that no human study has measured for these molecules. Muscle, fat, sleep, recovery, anti-aging and similar outcomes are named only to say that they have not been studied for CJC-1295 ipamorelin.

5. Testimonials and reviews

None. The site publishes no personal accounts, no reviews, no ratings, no before-and-after material, and does not invent them.

6. Status

Every page states that CJC-1295 and ipamorelin are investigational compounds, not approved by the FDA or the EMA, and that the content is informational and not medical advice.

7. Publisher

Disclosure: the publisher of this site also runs the OXpeptides shop, cited on these pages. Every fact is dated and sourced so you can check it yourself. The main page therefore lists the checks a buyer can make on any listing, instead of asking the reader to trust the publisher. The site accepts no advertising and carries no analytics or tracking script.

8. Dates

Each article shows the date it was published and the date it was last updated. Sources are re-verified when an article is updated. Every article is signed by the editorial desk, and its page lists each guide with its last update.

9. Corrections

Errors are corrected on the page, the updated date is changed, and a note is added at the foot of the page when a figure changes. Correction requests go to contact@cjc-1295-ipamorelin.com. A request that cites a DOI or an NCT number is handled first; every request receives an answer.

Read next: about the site and its method, or start with the main article on CJC-1295 ipamorelin.

Informational content, not medical advice. CJC-1295 and ipamorelin are investigational research compounds, not approved by the FDA or the EMA for any use, sold for research use only, not for human or veterinary use.